Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 06 04:00PM ET
9.11
Dollar change
-0.03
Percentage change
-0.33
%
IndexRUT P/E- EPS (ttm)-1.55 Insider Own0.83% Shs Outstand71.12M Perf Week6.30%
Market Cap645.82M Forward P/E- EPS next Y-1.26 Insider Trans-2.64% Shs Float70.53M Perf Month24.62%
Income-103.52M PEG- EPS next Q-0.34 Inst Own56.20% Short Float32.38% Perf Quarter42.79%
Sales0.05M P/S12916.46 EPS this Y18.24% Inst Trans-6.73% Short Ratio7.64 Perf Half Y41.13%
Book/sh1.88 P/B4.86 EPS next Y7.39% ROA-65.84% Short Interest22.84M Perf Year32.41%
Cash/sh1.97 P/C4.63 EPS next 5Y- ROE-72.96% 52W Range4.71 - 14.84 Perf YTD-19.02%
Dividend Est.- P/FCF- EPS past 5Y35.74% ROI-76.77% 52W High-38.61% Beta0.15
Dividend TTM- Quick Ratio16.87 Sales past 5Y115.21% Gross Margin-3928.85% 52W Low93.42% ATR (14)0.84
Dividend Ex-DateJan 20, 2017 Current Ratio16.87 EPS Y/Y TTM-1.24% Oper. Margin-191365.38% RSI (14)58.96 Volatility10.55% 11.70%
Employees59 Debt/Eq0.01 Sales Y/Y TTM-81.36% Profit Margin-199076.92% Recom1.44 Target Price21.25
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q16.61% Payout- Rel Volume1.11 Prev Close9.14
Sales Surprise614.29% EPS Surprise10.26% Sales Q/Q-98.62% EarningsNov 12 BMO Avg Volume2.99M Price9.11
SMA207.24% SMA5023.34% SMA20020.33% Trades Volume3,306,607 Change-0.33%
Date Action Analyst Rating Change Price Target Change
Nov-12-24Initiated UBS Buy $26
Apr-29-24Downgrade Guggenheim Buy → Neutral
Jan-24-24Initiated Goldman Neutral $13
Mar-22-23Downgrade Goldman Buy → Neutral $20 → $6
Dec-01-22Initiated Goldman Buy $20
Dec-29-21Resumed Jefferies Buy $30
Jun-02-21Initiated H.C. Wainwright Buy $35
Feb-11-21Initiated Guggenheim Buy $36
Dec-14-20Initiated Jefferies Buy $25
Nov-12-20Reiterated B. Riley Securities Buy $31 → $28
Dec-03-24 06:22PM
Dec-02-24 07:30AM
07:30AM
Nov-26-24 07:30AM
Nov-15-24 11:00AM
07:00AM Loading…
Nov-12-24 07:00AM
Nov-11-24 07:30AM
07:30AM
Nov-07-24 07:30AM
Nov-06-24 07:30AM
Nov-04-24 07:30AM
Oct-15-24 08:00AM
Oct-01-24 07:30AM
Sep-30-24 07:30AM
Sep-10-24 01:09PM
07:45AM Loading…
07:45AM
Sep-03-24 07:30AM
Aug-08-24 07:00AM
Aug-07-24 07:00AM
Aug-01-24 07:30AM
Jul-25-24 07:30AM
Jul-09-24 06:42AM
Jul-06-24 08:00AM
Jul-02-24 07:30AM
Jun-28-24 10:09AM
01:55AM
Jun-26-24 11:08PM
07:30AM
Jun-24-24 06:02PM
03:52PM
11:13AM Loading…
11:13AM
10:56AM
Jun-23-24 01:45PM
Jun-22-24 04:45PM
Jun-21-24 05:45AM
Jun-20-24 07:30AM
Jun-18-24 07:30AM
Jun-12-24 10:00AM
Jun-05-24 07:00AM
Jun-04-24 06:00AM
May-29-24 07:31AM
07:30AM
May-27-24 02:56PM
May-23-24 05:45AM
May-21-24 02:53PM
09:00AM
May-20-24 03:01PM
May-17-24 06:15AM
May-15-24 05:45AM
May-14-24 12:47PM
May-10-24 03:58PM
May-09-24 11:57AM
07:00AM
May-08-24 08:50AM
May-07-24 07:30AM
May-02-24 07:30AM
May-01-24 07:30AM
Apr-25-24 05:24PM
Mar-29-24 12:00PM
Mar-28-24 10:49AM
Mar-27-24 06:29PM
11:53AM
07:58AM
07:00AM
Mar-20-24 07:30AM
Feb-26-24 09:26AM
Feb-20-24 10:26AM
Feb-13-24 03:07PM
Jan-02-24 07:30AM
Dec-01-23 11:45AM
04:47AM
Nov-30-23 04:24PM
Nov-08-23 09:15AM
Nov-07-23 07:00AM
Oct-31-23 07:30AM
Oct-26-23 07:30AM
Oct-25-23 07:30AM
Oct-17-23 07:30AM
Sep-26-23 07:30AM
Sep-12-23 07:30AM
Aug-30-23 07:30AM
Aug-10-23 07:00AM
Aug-03-23 07:30AM
Aug-01-23 07:30AM
Jun-27-23 09:56AM
Jun-16-23 07:30AM
Jun-15-23 07:30AM
May-31-23 07:30AM
May-11-23 07:00AM
May-08-23 07:30AM
May-04-23 07:30AM
Apr-11-23 07:30AM
Mar-27-23 04:05PM
Mar-21-23 07:00AM
Feb-28-23 07:00AM
Feb-21-23 07:30AM
Jan-04-23 07:30AM
07:30AM
Dec-20-22 07:00AM
Nov-22-22 07:30AM
Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Drutz DavidDirectorAug 19 '24Option Exercise2.5541,750106,37563,708Aug 20 06:05 PM
Drutz DavidDirectorAug 19 '24Sale6.9016,011110,54741,958Aug 20 06:05 PM
Roberts M ScotChief Scientific OfficerFeb 02 '24Option Exercise0.007,775044,990Feb 05 06:02 PM
Roberts M ScotChief Scientific OfficerFeb 01 '24Option Exercise0.006,166039,016Feb 05 06:02 PM
Harris Matthew ScottChief Medical OfficerFeb 02 '24Option Exercise0.007,775055,965Feb 05 06:01 PM
Harris Matthew ScottChief Medical OfficerFeb 01 '24Option Exercise0.006,166049,991Feb 05 06:01 PM
Garg Vipin KPresident and CEOFeb 02 '24Option Exercise0.0018,9500300,404Feb 05 06:00 PM
Garg Vipin KPresident and CEOFeb 01 '24Option Exercise0.0016,5450288,767Feb 05 06:00 PM
Roberts M ScotChief Scientific OfficerJan 30 '24Option Exercise0.009,275029,699Feb 01 06:03 PM
Harris Matthew ScottChief Medical OfficerJan 30 '24Option Exercise0.009,275043,277Feb 01 06:01 PM
Garg Vipin KPresident and CEOJan 30 '24Option Exercise0.0026,7750276,030Feb 01 06:01 PM
Eisenstadt Richard IChief Financial OfficerJan 30 '24Option Exercise0.009,275042,566Feb 01 06:00 PM
Jordt Raymond MChief Business OfficerJan 01 '24Option Exercise0.009,375011,207Jan 04 06:00 PM
Eisenstadt Richard IChief Financial OfficerDec 29 '23Option Exercise0.0012,500036,335Jan 02 06:00 PM